Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?

Shares of Day One Biopharmaceuticals, Inc. (DAWN) have gained 10.7% over the past four weeks to close the last trading session at $15.15, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$35.88 indicates a potential upside of 136.8%.The average comprises eight short-term price targets ranging from a low of $28 to a high of$44, with a standard deviation of $5.19. While the lowest ...